Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

"This rise is primarily observed in countries in the Eastern Mediterranean, Southeast Asia and Western Pacific regions. Since ...

World Health Organisation (WHO) has identified the new COVID variant, NB.1.8.1, detected in January, as a descendant of ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

As society becomes more relaxed about the perceived threat of Covid-19, the coronavirus has started to resurge in many ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...